DEVELOPMENT AND VALIDATION OF A HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY METHOD FOR ASSAY DETERMINATION OF ERLOTINIB HCL IN TABLET DOSAGE FORM
Erlotinib HCl is a compound widely used in the treatment of non-small cell lung cancer (NSCLC) and pancreatic cancer. The determination of Erlotinib levels in tablet formulations is essential to ensure the ef icacy and safety of the medication. The development of this analysis method was carried...
Saved in:
Main Author: | |
---|---|
Format: | Theses |
Language: | Indonesia |
Online Access: | https://digilib.itb.ac.id/gdl/view/81103 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Institution: | Institut Teknologi Bandung |
Language: | Indonesia |
Summary: | Erlotinib HCl is a compound widely used in the treatment of non-small cell lung
cancer (NSCLC) and pancreatic cancer. The determination of Erlotinib levels in
tablet formulations is essential to ensure the ef icacy and safety of the medication. The
development of this analysis method was carried out using a Waters HPLC
instrument with a stationary phase consisting of a L7 4.6 x 250 mm, 5 ?m (Zorbax)
column, an isocratic mobile phase of pH 3 buf er and acetonitrile (72:28), a column
temperature of 30°C, UV-Vis detector at a wavelength of 247 nm, and a flow rate of
1.5 mL/min. Optimization of sonication time and filter compatibility was performed
before the analysis method validation. Sonication time optimization was conducted by
examining the Erlotinib HCl content in tablets with variations of 5 minutes, 10
minutes, and 30 minutes, resulting in 102.7%, 102.1%, and 102.9% recoveries, respectively, with no dif erence in results between each time. Filter compatibility
optimization was carried out using variations of PVDF, PTFE, Nylon, and RC filters
with comparison solution, yielding % recoveries between filters of 99.4%, 99.4%, 100.6%, and 100.4%, respectively.Validation of the analysis method was conducted
according to ICH Q2 and USP guidelines, covering parameters such as specificity, linearity, accuracy, precision, and robustness (solution stability). The validation
results showed that the developed HPLC method can provide a specific, linear, accurate, and precise method for analyzing Erlotinib HCl in tablet formulations, with
no solvent and placebo interference at the Erlotinib retention time, an average %
recovery for 3 concentration levels of 70-130% of 101.2%, and % RSD for 9 accuracy
data and % RSD for 12 data with analyst, instrument, and laboratory dif erences of
0.3% and 1.7%, respectively. Based on the research, the variation in buf er pH shows
that within the pH range of 2.8-3.2, the critical parameter results are still within
acceptable limits. Additionally, the results of standard solution and sample solution
stability showed stability for 24 hours at room temperature. Based on the results of
method development and validation, it can be concluded that the analysis method is
valid for quality control purposes and regulatory compliance. |
---|